This week in drug discovery (5-9 September)

News round-up for 5-9 September by DDW Digital Content Editor Diana Spencer

Cancer research has been making headlines over the last seven days in the build-up to the European Society for Medical Oncology (ESMO) Congress 2022.

Notably, it was a mixed week for PARP inhibitor olaparib, which was approved by regulator the MHRA for patients with early-stage breast cancer, but rejected by NICE for use on the NHS in metastatic prostate cancer.

This week’s top stories:

Combination therapy halts lung cancer tumour growth in mice

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a recent study.

Soft tissue sarcoma drug receives FDA Orphan Designation 

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma. 

Researchers “eradicate” untreatable brain cancer 

A study at Tel Aviv University is said to have eradicated glioblastoma, a highly aggressive type of brain cancer.

Pleco Therapeutics raises €17.3m to progress leukaemia drug

Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML).

NICE rejects prostate cancer drug due to cost of genetic testing 

The National Institute of Health and Care Excellence (NICE) has confirmed its decision not to recommend olaparib for previously treated metastatic prostate cancer in patients with BRCA gene mutations.










Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free